Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

被引：63

作者：

Iankov, Ianko D. ^{[1
]}

Msaouel, Pavlos ^{[1
]}

Allen, Cory ^{[1
]}

Federspiel, Mark J. ^{[1
]}

Bulur, Peggy A. ^{[1
]}

Dietz, Allan B. ^{[1
]}

Gastineau, Dennis ^{[1
]}

Ikeda, Yasuhiro ^{[1
]}

Ingle, James N. ^{[1
]}

Russell, Stephen J. ^{[1
]}

Galanis, Evanthia ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN 55905 USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2010年 / 122卷 / 03期

关键词：

Measles virus; Pleural effusion; Breast cancer; Oncolytic virotherapy; GREEN FLUORESCENT PROTEIN; IN-VIVO; VACCINE STRAIN; TUMOR-CELLS; THERAPY; TRANSDUCTION; PLEURODESIS; XENOGRAFTS; MANAGEMENT; INFECTION;

D O I：

10.1007/s10549-009-0602-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the second leading cause of malignant effusions in cancer patients. Pleural effusion indicates incurable disease with limited palliative treatment options and poor outcome. Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer. Both systemic intravenous (i.v.) and intrapleural (t.t.) administered virus caused massive infection and syncytia formation in the pleural tumor deposits. Intrapleural administration of 1.5 x 10(6) plaque-forming units (PFU) total dose of MV significantly improved median survival by approximately 80% compared to the control animal group. Furthermore, we tested human dendritic cells as carriers for delivery of oncolytic MV infection to breast cancer pleural metastases. Carrier-delivered MV infection prevented accumulation of the pleural exudate and also significantly improved the survival of the treated mice. This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer.

引用

页码：745 / 754

页数：10

共 32 条

[1] High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus [J].